Biocon Biologics gets US FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market
NEW DELHI: Biocon Biologics announced that the US Food and Drug Administration (US FDA) has approved the company’s application for YESAFILI, the company informed the exchange in a filing.“Biocon Biologics’ Obtains US FDA Approval for Biosimilar Aflibercept for Yesafili. Enters US Ophthalmology Market” said the company.After the approval, the company entered the ophthalmology therapeutic area … Read more